Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Analytical validation of automated bone scan index (BSI) as an imaging biomarker in patients with metastatic prostate cancer (mPC)
    Meeting Abstract

    Anand, A.; Morris, M.; Minarik, D.; Bjartell, A.; Edenbrandt, L.
    Journal of Nuclear Medicine (2015)

    Fulltext@MSK | Save
  • Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor
    Meeting Abstract

    Zanna, C.; Vaslin, A.; Voss, M. H.; Heist, R. S.; Hierro, C.; Supko, J. G.; Nakai, K.; Ishii, N.; Menetrey, A.; Roubaudi-Fraschini, M. C.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Comprehensive characterization of cisplatin-related hearing loss in US and Canadian Testicular Cancer Survivors (TCS)
    Meeting Abstract

    Wheeler, H. E.; Travis, L. B.; Budnick, A.; Feldman, D. R.; Einhorn, L. H.; Hamilton, R. J.; Vaughn, D. J.; Beard, C.; Fung, C.; Johnson, E.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Plimack, E. R.; Rini, B. I.; Atkins, M. B.; Alter, R.; Bhatt, R. S.; Beck, J. T.; Mutyaba, M.; Pappas, K. M.; Wilson, D.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features
    Meeting Abstract

    Voss, M. H.; Chen, Y. B.; Chaim, J.; Coskey, D. T.; Woo, K.; Redzematovic, A.; Wang, P.; Lee, W.; Patil, S.; Molina, A. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Plimack, E. R.; Rini, B. I.; Atkins, M. B.; Alter, R.; Bhatt, R. S.; Beck, J. T.; Mutyaba, M.; Pappas, K. M.; Wilson, D.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC)
    Meeting Abstract

    Voss, M. H.; Coates, A.; Garmey, E. G.; Haas, N. B.; Hutson, T.; Keefe, S. M.; Motzer, R.; Piscitelli, A.; Vogelzang, N. J.; Figlin, R. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Prospective identification of potentially actionable molecular alterations in cancers of unknown primary
    Meeting Abstract

    Varghese, A. M.; Hyman, D. M.; Zehir, A.; Vakiani, E.; Klimstra, D. S.; Ladanyi, M.; Berger, M. F.; Solit, D. B.; Saltz, L.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC)
    Meeting Abstract

    Thompson, J. A.; Motzer, R.; Molina, A. M.; Choueiri, T. K.; Heath, E. I.; Kollmannsberger, C. K.; Redman, B. G.; Sangha, R. S.; Ernst, D. S.; Pili, R.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Effect of radium-223 dichloride (Ra-223) on pain from US EAP
    Meeting Abstract

    Sweeney, C.; Sartor, A. O.; Vogelzang, N. J.; Shore, N. D.; Cislo, P.; Bangerter, K.; Morris, M. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save